Compare Amphastar Pharmaceuticals Inc (AMPH) vs CF Industries Holdings, Inc. (CF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs CF Industries Holdings, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.33 (market cap $826.08M), while CF Industries Holdings, Inc. trades at $120.38 (market cap $17.96B). The key difference: CF Industries Holdings, Inc. is far larger — about 21.7× Amphastar Pharmaceuticals Inc's market cap, and CF Industries Holdings, Inc. pays a 2.05% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CF | |
|---|---|---|
Market Cap | $826.08M | $17.96B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $137.55 |
52-Week Low | $16.87 | $76.08 |
Enterprise Value | $1.22B | $19.54B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
CF Industries (CF) trades at $116.92, up 2.54% today, with strong bullish momentum from earnings beats and a 20% dividend increase announced July 8, 2026. The stock shows robust fundamentals with a P/E of 10.53 and ROE of 34.74%, while technical indicators signal bullish moving averages but overbought RSI levels near 76. Revenue growth rebounded to $7.08B in 2025 after a dip, supported by firm nitrogen demand.
Outlook remains positive with a consensus price target of $126.67, though risks include rising natural gas costs pressuring margins. The stock offers value and income appeal, but investors should monitor input cost trends and Q2 2026 earnings against expectations of $5.71 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About CF Industries Holdings, Inc.
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →
